Used as a key intermediate in the synthesis of peptide-based pharmaceuticals, particularly in the development of protease inhibitors. Its structure allows for selective coupling in solid-phase peptide synthesis, making it valuable for creating complex bioactive molecules. The presence of the cyanophenyl group enhances binding specificity, while the Fmoc group enables mild deprotection conditions, preserving sensitive functional groups during synthesis. Commonly employed in research settings for designing targeted therapies, including antiviral and anticancer agents.